Research & Development
Fujirebio introduces blood-based RUO Alzheimer’s assays
The assays, which are for the quantitative measurement of E4 isoform of the apolipoprotein E (ApoE4) and all isoforms of the same protein (Pan-ApoE), respectively, extend Fujirebio’s current portfolio of RUO biomarker assays for the Lumipulse G system.
March 31, 2023
Study takes aim at blood test for multiple pathways implicated in Alzheimer's disease
The study may ultimately lead to more personalized patient care through the development of a blood test for multiple pathways implicated in the disease, the researchers said.
March 29, 2023
Roche, Lilly partner on early diagnosis of Alzheimer's disease
The firms are developing one of Roche's panels, which measures phosphorylated Tau (pTau) 181 protein and apolipoprotein (APOE) E4 in human blood plasma.
March 22, 2023
Rowan University, Durin Technologies tout preliminary results for early Alzheimer's blood test
Using eight autoantibody biomarkers, the test identified the presence of Alzheimer's disease pathology across the disease's progression, including among those originally determined to have no trace of the disease, the researchers said.
March 8, 2023
AriBio, Fujirebio partner on biomarker development for Alzheimer’s, other neurodegenerative disorders
The agreement will provide Fujirebio access to clinical samples and data that have been collected in an ongoing phase III Alzheimer’s disease study being conducted by AriBio.
March 8, 2023
Modifying messenger RNA provides new Alzheimer’s disease target
Reducing methylation of a key messenger RNA can promote macrophage migration into the brain and ameliorate Alzheimer’s disease symptoms in mice.
March 7, 2023
Analysis of genome-wide methylomic variations reveal epigenetic changes in Alzheimer’s brains
Multiple papers have already described DNA methylation differences associated with Alzheimer’s and other forms of dementia in several regions of the brain.
February 22, 2023
Blood biomarker facilitates vascular dementia diagnosis
In a study, researchers hypothesized that the body might respond to damaged small blood vessels with intensified efforts to grow more vessels, and they identified the signaling involved in the formation of new blood vessels.
February 23, 2023
Alzheimer’s disease testing firm C2N nabs additional $15M in financing
C2N will allocate part of the additional financing to support its new generation blood test, PrecivityAD2, designed to aid in the diagnosis of Alzheimer's disease.
February 17, 2023
Blood test may predict Alzheimer’s 3.5 years before diagnosis
Researchers have developed a blood-based test that can predict the risk of Alzheimer’s disease up to 3.5 years before clinical diagnosis.
January 30, 2023
Synaps Dx touts importance of skin sample test given FDA's recent Alzheimer's treatment approval
The firm's Discern test, which requires a small skin sample taken by a certified healthcare provider, is autopsy-validated to identify Alzheimer’s disease in people recently diagnosed with dementia.
January 17, 2023
Biomarkers reveal Alzheimer’s years before symptoms show
The study, published January 11 in the journal Brain, could potentially lead to earlier detection of this serious disease.
January 11, 2023
Page 1 of 6